Clinical and functional responses in patients who switched treatments, 3 and 6 months postswitch (as observed)
| n/N (%) | UPA 15 mg once daily to ADA (N=251) | ADA to UPA 15 mg once daily (N=159) | ||
| 3 months postswitch | 6 months postswitch | 3 months postswitch | 6 months postswitch | |
| DAS28(CRP) ≤3.2 | 71/233 (30.5) | 91/230 (39.6) | 77/150 (51.3) | 82/147 (55.8) |
| DAS28(CRP) <2.6 | 34/233 (14.6) | 49/230 (21.3) | 45/150 (30.0) | 51/147 (34.7) |
| CDAI ≤10 | 74/242 (30.6) | 95/234 (40.6) | 58/148 (39.2) | 77/146 (52.7) |
| CDAI ≤2.8 | 8/242 (3.3) | 12/234 (5.1) | 13/148 (8.8) | 22/146 (15.1) |
| SDAI ≤11 | 69/231 (29.9) | 96/229 (41.9) | 64/144 (44.4) | 77/145 (53.1) |
| SDAI ≤3.3 | 9/231 (3.9) | 11/229 (4.8) | 12/144 (8.3) | 26/145 (17.9) |
| Mean change from baseline (95% CI)* | ||||
| HAQ-DI | −0.56 (−0.64 to −0.48) | −0.58 (-0.66 to −0.49) | −0.69 (−0.79 to −0.60) | −0.73 (−0.83 to −0.63) |
| DAS28(CRP) | −2.13 (−2.3 to −1.96) | −2.40 (−2.58 to −2.22) | −2.74 (−2.96 to −2.52) | −2.88 (−3.11 to −2.65) |
| CDAI | −24.94 (−26.86 to −23.01) | −27.28 (−29.35 to −25.21) | −27.01 (−29.63 to −24.56) | −29.47 (−32.23 to −26.71) |
| SDAI | −25.80 (−27.84 to −23.76) | −28.30 (−30.45 to −26.15) | −28.57 (−31.31 to −25.84) | −31.02 (−33.86 to −28.19) |
*Mean change from baseline at randomisation.
ADA, adalimumab; CDAI, Clinical Disease Activity Index; DAS28(CRP), 28-joint disease activity score based on C-reactive protein; HAQ-DI, Health Assessment Questionnaire Disability Index; SDAI, Simplified Disease Activity Index;UPA, upadacitinib.